Eurofins Scientific (ERFSF) 294.5500 $ERFSF
Ampersand Sells ViraCor-IBT To Eurofins For $255 Million
PR Newswire - Tue Jul 01, 8:00AM CDT
Ampersand Capital Partners has completed the sale of majority owned portfolio company ViraCor-IBT Laboratories ("VIBT" or "ViraCor"
to Eurofins Scientific for $255 million. VIBT is a premier specialty testing laboratory, providing complex, high-value diagnostic tests to 550 institutional clients and more than 4,000 affiliated clinicians across the US with an emphasis on the transplant market. The Company will continue to be known as ViraCor-IBT, operating from its large, state-of-the art facility in the Kansas City area and its satellite laboratory in California.
2014 Report on the International In-Vitro Toxicology/ Toxicity Testing (Diagnostic, Pharmaceutical, Cosmetics, Chemical) Market - Forecast to 2018
M2 - Tue Jun 10, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2m7bzc/invitro) has announced the addition of the "2014 Report on the International In-Vitro Toxicology/ Toxicity Testing (Diagnostic, Pharmaceutical, Cosmetics, Chemical) Market - Forecast to 2018" report to their offering. Attributed to the support offered by the European government, the in vitro toxicology testing market in Europe was the largest in 2013 and is expected to hold the same stance by 2018. There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in experimentation is becoming dearer, primarily due to the costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues including concerns for animal welfare. Moreover the rates of drug attrition have also risen in recent years due to lesser availability of data on the toxicity profiles of the candidates that are under development process. To counteract these issues there has been a rise in the development of in vitro methods that are alternative to animal testing. A paradigm shift is observed towards emerging technologies such as assays based on human cells or non-mammalian models, high throughput testing, omics approaches, ex vivo models, and in silico techniques. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 By Industry 6 By Technology 7 By Application 8 By Method 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics For more information visit http://www.researchandmarkets.com/research/2m7bzc/invitro
Eurofins Brings Together the Expertise of MWG Operon and Medigenomix under a New Global Brand, Eurofins Genomics, to Provide Seamless Best-in-Class Genomics Services Worldwide
Business Wire - Wed Apr 02, 12:30AM CDT
Regulatory News:
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Bruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors
Business Wire - Mon Jan 13, 6:00AM CST
Bruker Corporation (NASDAQ:BRKR) announced the election of Dr. Gilles Martin to its Board of Directors, effective as of today.
Orion Diagnostica Oy and Eurofins Medigenomix enter into a license agreement on Orion Diagnostica Oy's proprietary SIBA(R) technology
GlobeNewswire - Tue Dec 17, 2:15AM CST
Eurofins Medigenomix, a part of the Eurofins Genomics Business line of Eurofins Scientific and Orion Diagnostica Oy, an in vitro diagnostics company specialising in the development, production and sales of diagnostic test systems, announced that they have signed a co-exclusive technology license agreement. Orion Diagnostica Oy owns the global rights for the SIBA(R) isothermal nucleic acid detection technology in all fields.
New genetic tools for differentiating "identical" twins: Eurofins develops first DNA test for forensic and paternity testing of twins
Business Wire - Tue Dec 10, 1:00AM CST
Regulatory News:
Testing Laboratories - Global Strategic Business Report
M2 - Thu Feb 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/fwt2rl/testing) has announced the addition of the "Testing Laboratories - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testing Laboratories in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Introduction To Testing Laboratories 3. Insight Into Select Testing Laboratories Services 4. Product/Service Launches 5. Recent Industry Activity 6. Strategic Corporate Developments
Food Safety Testing - Global Strategic Business Report
M2 - Fri Dec 21, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6hs4rq/food_safety) has announced the addition of the "Food Safety Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Food Safety Testing in US$ Million by the following Product Segments: Pathogens Testing, Pesticide Testing, GMO Testing, and Other Testing. The End-Use markets also analyzed in the report include Processed Food, Dairy, Meat, and Others (includes Fruits, Vegetables, and Juices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 112 companies including many key and niche players such as 3M Company, BioControl Systems, Inc., bioM?rieux SA, AES Chemunex SA, Biolog, Inc., Celsis International Ltd., Charm Sciences, Inc., DuPont Qualicon, Inc., FOSS A/S, Eurofins GeneScan Europe AG, Genetic
Ampersand Sells ViraCor-IBT To Eurofins For $255 Million
PR Newswire - Tue Jul 01, 8:00AM CDT
Ampersand Capital Partners has completed the sale of majority owned portfolio company ViraCor-IBT Laboratories ("VIBT" or "ViraCor"
to Eurofins Scientific for $255 million. VIBT is a premier specialty testing laboratory, providing complex, high-value diagnostic tests to 550 institutional clients and more than 4,000 affiliated clinicians across the US with an emphasis on the transplant market. The Company will continue to be known as ViraCor-IBT, operating from its large, state-of-the art facility in the Kansas City area and its satellite laboratory in California. 2014 Report on the International In-Vitro Toxicology/ Toxicity Testing (Diagnostic, Pharmaceutical, Cosmetics, Chemical) Market - Forecast to 2018
M2 - Tue Jun 10, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2m7bzc/invitro) has announced the addition of the "2014 Report on the International In-Vitro Toxicology/ Toxicity Testing (Diagnostic, Pharmaceutical, Cosmetics, Chemical) Market - Forecast to 2018" report to their offering. Attributed to the support offered by the European government, the in vitro toxicology testing market in Europe was the largest in 2013 and is expected to hold the same stance by 2018. There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in experimentation is becoming dearer, primarily due to the costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues including concerns for animal welfare. Moreover the rates of drug attrition have also risen in recent years due to lesser availability of data on the toxicity profiles of the candidates that are under development process. To counteract these issues there has been a rise in the development of in vitro methods that are alternative to animal testing. A paradigm shift is observed towards emerging technologies such as assays based on human cells or non-mammalian models, high throughput testing, omics approaches, ex vivo models, and in silico techniques. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 By Industry 6 By Technology 7 By Application 8 By Method 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics For more information visit http://www.researchandmarkets.com/research/2m7bzc/invitro
Eurofins Brings Together the Expertise of MWG Operon and Medigenomix under a New Global Brand, Eurofins Genomics, to Provide Seamless Best-in-Class Genomics Services Worldwide
Business Wire - Wed Apr 02, 12:30AM CDT
Regulatory News:
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Bruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors
Business Wire - Mon Jan 13, 6:00AM CST
Bruker Corporation (NASDAQ:BRKR) announced the election of Dr. Gilles Martin to its Board of Directors, effective as of today.
Orion Diagnostica Oy and Eurofins Medigenomix enter into a license agreement on Orion Diagnostica Oy's proprietary SIBA(R) technology
GlobeNewswire - Tue Dec 17, 2:15AM CST
Eurofins Medigenomix, a part of the Eurofins Genomics Business line of Eurofins Scientific and Orion Diagnostica Oy, an in vitro diagnostics company specialising in the development, production and sales of diagnostic test systems, announced that they have signed a co-exclusive technology license agreement. Orion Diagnostica Oy owns the global rights for the SIBA(R) isothermal nucleic acid detection technology in all fields.
New genetic tools for differentiating "identical" twins: Eurofins develops first DNA test for forensic and paternity testing of twins
Business Wire - Tue Dec 10, 1:00AM CST
Regulatory News:
Testing Laboratories - Global Strategic Business Report
M2 - Thu Feb 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/fwt2rl/testing) has announced the addition of the "Testing Laboratories - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testing Laboratories in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Introduction To Testing Laboratories 3. Insight Into Select Testing Laboratories Services 4. Product/Service Launches 5. Recent Industry Activity 6. Strategic Corporate Developments
Food Safety Testing - Global Strategic Business Report
M2 - Fri Dec 21, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6hs4rq/food_safety) has announced the addition of the "Food Safety Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Food Safety Testing in US$ Million by the following Product Segments: Pathogens Testing, Pesticide Testing, GMO Testing, and Other Testing. The End-Use markets also analyzed in the report include Processed Food, Dairy, Meat, and Others (includes Fruits, Vegetables, and Juices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 112 companies including many key and niche players such as 3M Company, BioControl Systems, Inc., bioM?rieux SA, AES Chemunex SA, Biolog, Inc., Celsis International Ltd., Charm Sciences, Inc., DuPont Qualicon, Inc., FOSS A/S, Eurofins GeneScan Europe AG, Genetic
